Similarly, the application of precise inhibitors that specifically target genetic variations in the IL-6 gene, notably the rs1800795 polymorphism, effectively reduces inflammation and arrests the progression of osteomyelitis and PJI. The gene discussed is IL6; the disease is juvenile polyposis syndrome.